Market Access for Innovative Medicines in Azerbaijan.
Opportunities Within a Developing Healthcare System
Azerbaijan's healthcare system is undergoing a gradual transformation aimed at improving patient access to innovative medicines. While the country does not yet operate a comprehensive reimbursement system comparable to those in many European countries, access to medicines is increasingly supported through a combination of Mandatory Health Insurance (SAMHI) and disease-specific state programs funded directly by the government. The market access pathway begins with marketing authorization issued by the Ministry of Health following scientific evaluation by the Center of Analytical Expertise (CAE). After registration, most prescription medicines require price approval before commercialization. Once available on the market, access depends on the therapeutic area and the applicable funding mechanism.
Unlike countries with broad outpatient reimbursement lists, Azerbaijan has historically relied on vertical national health programs, under which medicines are centrally procured and provided free of charge to eligible patients. These programs ensure access to treatment for several high-priority diseases and represent the primary public funding mechanism for innovative therapies. Today, government-funded programs cover a number of serious and chronic conditions, including:
Diabetes mellitus;
Hemophilia and thalassemia;
Chronic kidney disease and renal replacement therapy;
Tuberculosis;
HIV/AIDS;
Multiple sclerosis;
Oncology;
Maternal and child health;
Immunization and infectious disease prevention.
These disease-specific programs are complemented by the Mandatory Health Insurance (SAMHI) system, which finances a growing package of inpatient and outpatient healthcare services. Recent reforms have also announced an ambulatory medicine reimbursement, creating a new financing mechanism through contracted pharmacies. This mechanism is expected to be launched since January 2027.
Although currently limited in scope, this represents an important step toward expanding access to outpatient medicines beyond traditional state programs.
Looking ahead, Azerbaijan is expected to continue strengthening its reimbursement framework by gradually expanding outpatient medicine coverage while maintaining targeted funding for high-priority diseases. For pharmaceutical companies introducing innovative therapies—particularly in rare diseases, oncology, immunology, and metabolic disorders—understanding both the regulatory process and the country's evolving public financing mechanisms is essential for successful market entry. As healthcare financing continues to evolve, companies that develop an early market access strategy and engage with national stakeholders will be well positioned to bring innovative therapies to Azerbaijani patients. For pharmaceutical companies, Azerbaijan represents an attractive emerging market with increasing demand for innovative therapies, particularly in oncology, rare diseases, immunology, endocrinology, and other specialty therapeutic areas. Companies that engage early with local stakeholders and develop a tailored market access strategy can successfully navigate the regulatory environment and identify the most appropriate funding pathway for their products.
If you are a European or US pharmaceutical company developing innovative, specialty, or complex generic medicines and are considering entering the Azerbaijani market, Nexa Pharm can support your journey—from regulatory strategy and product registration to pricing, market access, commercialization, and local representation.